R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and ...

BBO-8520, an investigational oral agent, has been granted fast track designation from the FDA in previously treated KRAS G12C ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

R289 has gained orphan drug status from the FDA for the treatment of patients with myelodysplastic syndromes. The FDA has ...

The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...